By Catherine Fredenburgh ( July 20, 2006, 12:00 AM EDT) -- New York-based ImClone Systems Inc. and Germany-based Merck KGaA have agreed to amend a 1998 development and licensing agreement that covers the blockbuster cancer drug Erbitux and other epidermal growth factor receptor, or EGFR, targeted antibodies....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.